1. Home
  2. TAYD vs ADCT Comparison

TAYD vs ADCT Comparison

Compare TAYD & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Taylor Devices Inc.

TAYD

Taylor Devices Inc.

N/A

Current Price

$59.50

Market Cap

165.2M

Sector

Industrials

ML Signal

N/A

Logo ADC Therapeutics SA

ADCT

ADC Therapeutics SA

N/A

Current Price

$1.07

Market Cap

136.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TAYD
ADCT
Founded
1955
2011
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
165.2M
136.1M
IPO Year
1995
2019

Fundamental Metrics

Financial Performance
Metric
TAYD
ADCT
Price
$59.50
$1.07
Analyst Decision
Hold
Strong Buy
Analyst Count
1
4
Target Price
$70.00
$7.75
AVG Volume (30 Days)
40.8K
1.7M
Earning Date
03-31-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
30.86
EPS
2.62
N/A
Revenue
$41,649,673.00
$81,357,000.00
Revenue This Year
$0.25
N/A
Revenue Next Year
$19.78
$66.49
P/E Ratio
$22.65
N/A
Revenue Growth
N/A
14.85
52 Week Low
$40.50
$0.78
52 Week High
$90.37
$4.98

Technical Indicators

Market Signals
Indicator
TAYD
ADCT
Relative Strength Index (RSI) 53.79 44.74
Support Level $57.54 $0.98
Resistance Level $62.30 $1.20
Average True Range (ATR) 1.78 0.09
MACD -0.20 -0.01
Stochastic Oscillator 26.92 22.22

Price Performance

Historical Comparison
TAYD
ADCT

About TAYD Taylor Devices Inc.

Taylor Devices Inc is involved in the design, development, manufacture, and marketing of shock absorption, rate control, and energy storage devices for use in various types of machinery, equipment, and structures. The company's product line includes Seismic dampers, Fluidicshoks, Crane and industrial buffers, Self-adjusting shock absorbers, Liquid die springs, and Vibration Dampers. Its products are generally used to absorb, control, or mitigate the motion of masses caused by earthquakes or explosions. The company markets its products to various industries such as industrial, steel mills, buildings, bridges, aerospace, defense, and automotive industries.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Share on Social Networks: